Brain Cancer
Temporal Lobe Glioblastoma
Female, 36 years
Patient Internal 103600474
ICD-10 code
Diagnosis (Incl. Metastases/Stage) and Year
May 2020
Oligodendroglioma of the Temporal Lobe G3, 1p19q Coreletion (+), MGMT (+).
Previous Treatment
Surgery (Craniotomy), Radiation Therapy, Chemotherapy (Procarbazine, Lomustine, Vincristine).
Prognosis and Survival Expectation
The prognosis remains good, the median overall survival is 14.1 years for WHO Grade 3, 1p/19q Co-deleted Oligodendroglioma. The relative 5-year survival rate for Oligodendroglioma is 74.1%, but many factors can
affect prognosis.
Treatment Provided
Autologous DCV (6 doses) and CIK (4 doses) over a period of 6 months. Additionally, the patient received Umbilical Cord Blood Derived NK Cells (3 doses) with Interleukin-2.
Patient Survival/Condition and Year
Date of Review: 01/01/2024
The patient has survived for 44 months since the diagnosis. No signs of disease recurrence in radiological images have been noticed. It can be concluded that the addition of Immunotherapy, alongside Chemotherapy and Radiation Therapy, has benefited patient in disease stabilisation. There are no signs of disease recurrence so far.
